Korean J Intern Med.  2009 Mar;24(1):73-75. 10.3904/kjim.2009.24.1.73.

Successful Treatment of Small-Cell Lung Cancer With Irinotecan in a Hemodialysis Patient With End-Stage Renal Disease

• Kim DM
• Kim HL
• Chung CH
• Park CY

• KMID: 1785646
• DOI: http://doi.org/10.3904/kjim.2009.24.1.73

Abstract

The prognosis of patients with end-stage renal disease has improved with advances in hemodialysis techniques. However, many patients who undergo hemodialysis suffer from various types of cancer. Limited data is available to guide clinical management of these patients who may have impaired renal function. Here, we report our experience with the use of irinotecan for the treatment of a hemodialysis patient with small-cell lung cancer and end-stage renal disease.

Keyword

Small-cell lung cancer; Hemodialysis; Irinotecan

MeSH Terms

Antineoplastic Agents, Phytogenic/therapeutic use
Camptothecin/*analogs & derivatives/therapeutic use
DNA Topoisomerases, Type I/antagonists & inhibitors
Disease-Free Survival
Follow-Up Studies
Humans
Kidney Failure, Chronic/complications/*therapy
Lung Neoplasms/complications/*drug therapy
Male
Middle Aged
Renal Dialysis/*methods
Small Cell Lung Carcinoma/complications/*drug therapy